Read More

Extend Life Expectancy Against Aggressive Brain Cancers – Nano-Cap Firm Biodexa’s Investigational Drug Shows Potential

Biodexa Pharmaceuticals' MTX110, revolutionizing brain cancer treatment with innovative drug delivery technology. Early trials show promising survival rate extensions in Diffuse Midline Glioma and Recurrent Glioblastoma patients. Learn more about MTX110's potential.

BDRX

Read More

Insurance Coverage For Weight Loss Drugs – Elevance, CVS Health Become First To Extend Coverage To Novo Nordisk’s Successful Wegovy For Certain Patients

Major U.S. health insurers CVS Health, Elevance Health, and Kaiser Permanente now reimburse for Novo Nordisk's Wegovy for specific Medicare individuals with heart-related conditions. This shift aims to alleviate financial burden and may prompt broader coverage, potentially impacting drug spending.

CVS

Read More

Micro-Cap Avalo Therapeutics Stock Rallies As It Snaps AlmataBio For Ex-Eli Lilly Drug For Skin Disorder

Avalo Therapeutics shares are soaring after acquiring AVTX-009, a Phase 2-ready anti-IL-1β mAb. With $185 million in gross proceeds, Avalo aims to develop AVTX-009 for hidradenitis suppurativa and other chronic inflammatory indications. Chairman Garry Neil believes AVTX-009 holds immense potential in the multi-billion-dollar HS market.

AVTX